长托宁用于小儿鼾症麻醉前用药的临床观察

Effects of Penehyclidine Hydrochloride as Premdication on Children with Snoring Disease

目的 比较长托宁和阿托品用于小儿鼾症麻醉前给药后心率、血压，腺体分泌及术后并发症的影响。方法 选择年龄5—12岁，ASAI～Ⅱ级的小儿鼾症患儿40例，3例合并OSAS，均有打鼾史。随机分为2组：A组（长托宁组20例）和B组（阿托品组20例），术前30minA、B组患儿分别肌注长托宁、阿托品各0．01mg／kg，观察并记录给药后不同时点患儿ECG、MAP、SpO2、HR、呼吸道腺体分泌量及术后并发症。结果 A组给药后较给药前心率、血压差异无统计学意义（P〉0．05），B组心率明显升高（P〈0．05）。口腔分泌物量A组明显减少，术后并发症的发生率A组明显低于B组（P〈0、05）。结论 长托宁用于全麻下小儿鼾症术前给药安全有效，不影响心率、血压，能有效抑制腺体分泌，减少术后并发症发生率的作用。

Objective To compared the effects of penehyclidine hydrochloride and atropine as premedication for children with snore disease, and their influence on patient＇ s heart rate, blood pressure, gland secretion and postoperative complications. Methods 40 children with snoring disease （5 ～ 12 years old,ASA I ～ II ,3 children combined with OSAS） were divided into group A （ penehyclidine hydrochloride group,n = 20 ） and group B （ atropine group, n = 20 ） randomly. Penehyclidine hydrochloride and atropine were given respectively 30 min before operation, ECG, MAP, SpO2, HR, respiratory tract gland secretion and postoperative complications were observed and recorded. Results In group A, before and after administration, the differences of HR and blood pressure had no significant（ P〉 0.05 ）. While in group B, HR was increased significantly after administration （ P 〈 0.05 ）. Oral secretion and complications of group A were lower than that of group B （ P 〈0. 05 ）. Conclusions Penehyclidine hydrochloride is safe and effective as premedication for children with snoring disease under general anaesthesia,it have no influence on heart rate and blood pressure, and decrease the gland secretion and postoperative complications.